Navigation Links
Cancer researcher receives $3.8 million award from US Department of Defense
Date:11/13/2008

(Santa Barbara, Calif.) A $3.8 million Innovator Award, from the Department of Defense, is being granted over five years to an internationally renowned cancer researcher at the University of California, Santa Barbara.

Erkki Ruoslahti, recipient of the award, is known for his innovative, interdisciplinary research. "This is a special award because there are only four of them," said Ruoslahti. "I am very happy at being chosen." The award is designed to further his current research.

Ruoslahti's lab made a major advance in the past year. "I think that was part of the reason why the grant was awarded to me, is that we can now make probes, typically peptides," he said. "These are small pieces of protein that not only bind the particles to the vessels in the tumor, but they also carry the particles into the interior of the tumor, outside the blood vessels."

He recently showed that targeting a nanoparticle drug into a tumor is more effective than if it isn't targeted. "What we are working on now, as an additional function, is that we'd like to make the particles respond to a signal so that they would release a drug when we want it to be released," he said. "But we haven't solved what would have to be done to get that technology to work."

"We work a lot with nanoparticles; that is one of the reasons why I am here at UCSB," said Ruoslahti. "There are a lot of materials scientists here who are collaborating with us in designing the smart nanoparticles that seek out and zero in on the tumor."

Tumors have and this is one of the main problems in chemotherapy, or any other kind of tumor therapy a very high interstitial pressure. That pushes tissue fluid from the tumor out to the surrounding tissue. "That means that if you just have a drug, that you would like to enter into a tumor, this flow of fluid works against it and tends to push it out," he said. "We have now solved that problem with our newest peptides. We can get nanoparticles or just plain drugs to go through the tumor as if there were no obstacles there."

At Burnham-UCSB, Ruoslahti opened the Vascular Mapping Center which focuses on developing applications for vascular "zip codes," based on technology discovered in his laboratory. Vascular zip codes are molecular signatures in blood and lymphatic vessels (vasculature) that are specific to individual tissues and disease sites. Ruoslahti has discovered ways to selectively target drugs to tumor blood vessels in mice and suppress the growth of those tumors. He has also found a way to selectively target the lymphatic vessels in tumors. The hope is that this very specific delivery of therapeutics to tumor blood and lymphatic vessels will increase the efficacy of cancer therapies and decrease side effects.

Ruoslahti joined the faculty at UCSB as an adjunct professor in the Department of Molecular, Cellular, and Developmental Biology in 2006. He is affiliated with The Burnham Institute for Medical Research, an institute that is located both at UCSB and in San Diego. This type of collaboration, involving a highly ranked university and a nonprofit, independent research institute, exemplifies the inherent value of interdisciplinary research and the enhanced potential created when two such entities join force. Ruoslahti also belongs to the faculty of UC San Diego as a distinguished professor.


'/>"/>

Contact: Gail Gallessich
gail.g@ia.ucsb.edu
805-893-7220
University of California - Santa Barbara
Source:Eurekalert  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer researcher receives $3.8 million award from US Department of Defense
(Date:12/7/2016)... ... , ... Levels of a protein in the blood associated with heart disease ... the journal Radiology. , Heart disease and brain disease exact a major burden on ... population. Damage to both organs often occurs at a subclinical stage, or before signs ...
(Date:12/7/2016)... Camarillo, CA (PRWEB) , ... December 07, 2016 ... ... manufacturing high performance connectors, is now promoting to the US market its advanced ... SPRINGTAC®, ODU LAMTAC® and ODU TURNTAC®. These advanced technologies are ideal for ...
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a ... and business owners in the greater Dallas metropolitan area, is announcing a charity ... Foundation. , Established in 2009 by active police professionals in the Dallas region, ...
(Date:12/7/2016)... Queens, NY (PRWEB) , ... December 07, 2016 , ... ... to business owners and families throughout the Five Boroughs, is launching a charity drive ... League works to continue the traditions and spirit of marines and Navy FMF Corpsmen. ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink ... Network for connecting the Life Sciences supply chain ... marketplace, today announced that Tjoapack has selected TraceLink,s ... manufacturing customers comply with the rapidly approaching serialization ... Act (DSCSA) in 2017 and the EU Falsified ...
(Date:12/7/2016)... 7, 2016 According to a new market research ... Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, ... is expected to reach USD 1,519.2 Million by 2021 from USD 856.3 ... Continue Reading ... ...
(Date:12/7/2016)... NEW YORK , December 7, 2016 ... Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals ... DNAI ), and AveXis Inc. (NASDAQ: ... Biotechnology Sector Index fell roughly 37% to reach a level ... While it is down by approximately 14% for the year, ...
Breaking Medicine Technology: